scientific peer-review process and are overseen by the ORP. NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck
Search Results
Benjamin E. Greer, Ron E. Swensen, and Heidi J. Gray
carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma: A Gynecolog Oncology Group study (Abstr 1) . Gynecol Oncol 2003 ; 88 : 156 . 9 Ayhan A Tuncer ZS Tuncer R . Is routine appendectomy beneficial in the
Robert J. Morgan Jr., Ronald D. Alvarez, Deborah K. Armstrong, Barry Boston, Robert A. Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi J. Gray, Perry W. Grigsby, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Ursula A. Matulonis, David M. O'Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Russell J. Schilder, Julian C. Schink, Nelson Teng, and Theresa L. Werner
disease may also undergo intraperitoneal chemotherapy, although no randomized evidence for stage II disease has been published. 61 , 63 , 64 In women with stage III cancer, survival was increased by 16 months after intraperitoneal therapy using cisplatin/paclitaxel
William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Sarah L. Blair, Harold J. Burstein, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Jairam Krishnamurthy, Janice Lyons, P. Kelly Marcom, Jennifer Matro, Ingrid A. Mayer, Meena S. Moran, Joanne Mortimer, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Hope S. Rugo, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, John H. Ward, Jessica S. Young, Jennifer L. Burns, and Rashmi Kumar
endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab, and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up show that median PFS was comparable between
David M. O’Malley
ICON7. 1 , 2 A 3-arm trial that enrolled 1,873 patients with newly diagnosed stage III–IV ovarian cancer, GOG-0218 randomly assigned patients 1:1 to carboplatin/paclitaxel followed by placebo maintenance therapy; carboplatin/paclitaxel
Yi-Jen Chen
) for Anal Carcinoma recommend using 5-FU/cisplatin, carboplatin/paclitaxel, or FOLFOX (5-FU/leucovorin/oxaliplatin) as first-line treatment for MAC. 2 The recently reported randomized, international, multicenter, phase II InterAACT study found that
Presenters: Crystal S. Denlinger, Kristina A. Matkowskyj, and Mary F. Mulcahy
treatment options now exist that come on the heels of several negative phase II studies: the TyTAN trial of paclitaxel + lapatinib, 6 the GATSBY trial of trastuzumab emtansine (T-DM1) versus a taxane, 7 and the T-ACT trial of paclitaxel + trastuzumab. 8
Tanya E. Keenan and Sara M. Tolaney
atezolizumab and nab-paclitaxel (NCT01375842) showed a promising ORR of 39.4% in 33 patients, also treated with 0 to 2 prior lines, 27 perhaps related to the ability of taxanes to promote toll-like receptor activity and dendritic cell activation. 28 The
David Scott Miller, Gini Fleming, and Marcus E. Randall
paclitaxel: a Gynecologic Oncology Group study . Gynecol Oncol 2009 ; 112 : 543 – 552 . 13 Fleming GF Brunetto VL Cella D . Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial
Robert J. Morgan Jr
improvement in OS with less toxicity, because by the time it was published paclitaxel had already been proven to be a superior second agent, and the oncology community felt that intraperitoneal chemotherapy was not necessary in the age of the taxanes. Annual
